<DOC>
	<DOCNO>NCT00003661</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Umbilical cord blood transplantation may able replace cell destroy chemotherapy radiation therapy . PURPOSE : Phase II trial study effectiveness chemotherapy , radiation therapy , umbilical cord blood transplantation treat patient hematologic cancer .</brief_summary>
	<brief_title>Chemotherapy , Radiation Therapy , Umbilical Cord Blood Transplantation Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine rate hematologic immune reconstitution pediatric patient high risk hematologic malignancy first remission second subsequent remission , adult patient acute lymphocytic leukemia ( ALL ) acute nonlymphocytic leukemia ( ANLL ) second subsequent remission , undergo high dose chemoradiotherapy follow unrelated umbilical cord blood ( UCB ) transplantation . II . Determine incidence graft-versus-host disease set . III . Determine whether contamination umbilical cord blood maternal cell clinical problem setting . IV . Describe incidence leukemic relapse patient UCB transplantation . V. Describe incidence serious infection secondary lymphoproliferative disease follow transplantation UCB patient . VI . Determine specifically whether large recipient ( great 40 kg ) durably engraft unrelated UCB , determine whether nucleate cell progenitor cell content graft predictive hematological engraftment . OUTLINE : Patients undergo back-up bone marrow harvest prior treatment . Patients receive 9 fraction total body irradiation ( TBI ) day -9 -5 , follow melphalan IV day -4 -2 antithymocyte globulin IV methylprednisolone IV day -3 -1 . If TBI allow , busulfan substitute administer orally every 6 hour 4 day day -8 -5 . On day 0 , patient receive umbilical cord blood infusion . Cyclosporine methylprednisolone begin day -2 continue 6 month . Patients follow indefinitely survival late toxicity . PROJECTED ACCRUAL : A minimum 48 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignancy include : Pediatric acute lymphocytic leukemia ( ALL ) first complete remission high risk feature include presence ( 4 ; 11 ) ( 9 ; 22 ) , extreme hyperleukocytosis ( initial WBC great 500 K/mL ) , failure achieve complete remission standard induction therapy Adult ALL acute nonlymphoblastic leukemia ( ANLL ) first complete remission ( 8 ; 14 ) translocation failure achieve complete remission standard induction therapy ALL ANLL second subsequent remission Chronic myelogenous leukemia chronic accelerate phase Myelodysplastic syndrome evidence evolution acute myeloid leukemia Refractory anemia excess blast Refractory anemia excess blast transformation Chronic myelomonocytic leukemia Tlymphoblastic nonHodgkin 's lymphoma second subsequent remission Stage IV neuroblastoma Must also meet following condition : No HLAABC/DR identical relate bone marrow UCB donor No 5/6 antigen match related bone marrow UCB donor Condition preclude wait search find donor National Marrow Donor Registry Must available serologic match umbilical cord blood unit New York Blood Center 's Placental Blood Project No active CNS disease Not eligible COBLT study ( Transplantation Banked Umbilicial Cord Blood Cells Use Clinical Research Transplantation Umbilical Cord Blood Stem Progenitor Cells ) PATIENT CHARACTERISTICS : Age : Under 55 time umbilical cord blood transplantation Performance status : Zubrod 01 Lansky 80100 % Karnofsky 80100 % Life expectancy : At least 3 month Hematopoietic : Adequate hematologic status time backup bone marrow harvest : WBC least 3,000/mm3 Absolute neutrophil count least 1,000/mm3 Platelet count least 100,000/mm3 Hepatic : ALT/AST great 4 time normal Bilirubin great 2.0 mg/dL Renal : Creatinine great 2.0 mg/dL Creatinine clearance least 50 mL/min Cardiovascular : Normal cardiac function echocardiogram radionuclide scan ( shorten fraction ejection fraction least 80 % normal value age ) Pulmonary : FVC FEV1 least 60 % predicted age For adult : DLCO least 60 % predict Other : No active infection time backup bone marrow harvest pretransplant reduction Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>